Hepatitis ACT is Canberra’s community hepatitis organisation.
We are funded by ACT Health to deliver a comprehensive range of hepatitis related information, education, training, advocacy, policy, preventative and referral services. We aim to reduce transmission, and the associated morbidity and mortality, and to minimise the personal and social impacts.
Hepatitis ACT delivers a comprehensive range of services including hepatitis-related information and education, training and workforce development, health promotion, prevention (needle and syringe program), resource distribution, support, advocacy and referral.
Our vision
Continuing reduction in the prevalence of viral hepatitis, with people affected by hepatitis in our community:
making respected and meaningful contributions to decision making that affects their lives
having full access to relevant information, care, treatment and support, and
enjoying a full range of rights in keeping with Human Rights legislation and the Ottawa Charter, irrespective of culture, age, religion, sexuality, social or economic status and race.
Our values
We act with respect and integrity.
We enable self-determination.
We provide inclusive and confidential services.
We work together to be leaders in our field.
We value accountability and evidence based practice.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close